{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:20:09Z","timestamp":1786994409800,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.msard.2022.104038","type":"journal-article","created":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T02:28:29Z","timestamp":1657160909000},"page":"104038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Treatment with natalizumab during pregnancy in multiple sclerosis: The experience of implementing a clinical practice protocol (NAP-30)"],"prefix":"10.1016","volume":"66","author":[{"given":"Gabriel","family":"Valero-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Mill\u00e1n-Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Iniesta-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan L.","family":"Delgado-Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Jimenez-Veiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana B.","family":"Tejero-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelaida","family":"Le\u00f3n-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Zamarro-Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Morales-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5050-9890","authenticated-orcid":false,"given":"Jos\u00e9 E.","family":"Meca-Lallana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.msard.2022.104038_bib0001","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/jnnp-2020-323472","article-title":"Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis","volume":"91","author":"Chisari","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.msard.2022.104038_bib0002","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000723","article-title":"Monoclonal antibody treatment during pregnancy and\/or lactation in women with MS or neuromyelitis optica spectrum disorder","volume":"7","author":"Ciplea","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.msard.2022.104038_bib0003","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.neurol.2015.07.007","article-title":"Natalizumab throughout pregnancy: risk of low platelet count in the newborn at delivery","volume":"172","author":"Ciron","year":"2016","journal-title":"Rev. Neurol. (Paris)"},{"issue":"5","key":"10.1016\/j.msard.2022.104038_bib0004","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJM199807303390501","article-title":"Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group","volume":"339","author":"Confavreux","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.msard.2022.104038_bib0005","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/ane.12364","article-title":"Natalizumab discontinuation and disease restart in pregnancy: a case series","volume":"131","author":"De Giglio","year":"2015","journal-title":"Acta Neurol. Scand."},{"issue":"2","key":"10.1016\/j.msard.2022.104038_bib0006","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/practneurol-2018-002060","article-title":"UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines","volume":"19","author":"Dobson","year":"2019","journal-title":"Pract. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2022.104038_bib0007","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/1352458514546790","article-title":"Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study","volume":"21","author":"Ebrahimi","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104038_bib0008","unstructured":"EMA, S., 2021. Summary of Product Characteristics Tysabri\u00ae (natalizumab)."},{"issue":"1","key":"10.1016\/j.msard.2022.104038_bib0009","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12883-016-0674-4","article-title":"Evaluation of pregnancy outcomes from the Tysabri(R) (natalizumab) pregnancy exposure registry: a global, observational, follow-up study","volume":"16","author":"Friend","year":"2016","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2022.104038_bib0010","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1016\/j.msard.2017.06.005","article-title":"The 'Field Hypothesis': rebound activity after stopping disease-modifying therapies","volume":"15","author":"Giovannoni","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.msard.2022.104038_bib0011","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamaneurol.2014.209","article-title":"Natalizumab use during the third trimester of pregnancy","volume":"71","author":"Haghikia","year":"2014","journal-title":"JAMA Neurol."},{"issue":"8","key":"10.1016\/j.msard.2022.104038_bib0012","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1177\/1352458511401944","article-title":"Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment","volume":"17","author":"Hellwig","year":"2011","journal-title":"Mult. Scler."},{"issue":"6","key":"10.1016\/j.msard.2022.104038_bib0013","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1055\/s-0037-1608925","article-title":"Reproductive Issues in MS","volume":"37","author":"Houtchens","year":"2017","journal-title":"Semin. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2022.104038_bib0014","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1212\/CON.0000000000000745","article-title":"Pregnancy and Family Planning in Multiple Sclerosis","volume":"25","author":"Langer-Gould","year":"2019","journal-title":"Continuum (Minneap Minn)"},{"issue":"3","key":"10.1016\/j.msard.2022.104038_bib0015","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cgh.2012.11.011","article-title":"Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease","volume":"11","author":"Mahadevan","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.msard.2022.104038_bib0016","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2217\/nmt-2020-0049","article-title":"Identification of patients with relapsing multiple sclerosis eligible for high-efficacy therapies","volume":"11","author":"Meca-Lallana","year":"2021","journal-title":"Neurodegener. Dis. Manag."},{"issue":"9","key":"10.1016\/j.msard.2022.104038_bib0017","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.msard.2022.104038_bib0018","first-page":"e823","article-title":"Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks","volume":"90","author":"Portaccio","year":"2018","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2022.104038_bib0019","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1136\/jnnp-2013-306054","article-title":"Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs","volume":"85","author":"Portaccio","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"10","key":"10.1016\/j.msard.2022.104038_bib0020","first-page":"e832","article-title":"Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks","volume":"90","author":"Portaccio","year":"2018","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.msard.2022.104038_bib0021","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1177\/1352458517728813","article-title":"Natalizumab during pregnancy and lactation","volume":"24","author":"Proschmann","year":"2018","journal-title":"Mult. Scler."},{"issue":"10","key":"10.1016\/j.msard.2022.104038_bib0022","article-title":"Natalizumab for relapsing remitting multiple sclerosis","author":"Pucci","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"issue":"9","key":"10.1016\/j.msard.2022.104038_bib0023","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.msard.2022.104038_bib0024","doi-asserted-by":"crossref","first-page":"e1452","DOI":"10.1212\/WNL.0000000000008243","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","volume":"93","author":"Ryerson","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.104038_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103480","article-title":"No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: real-world evidence from MS PATHS","volume":"58","author":"Ryerson","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"10.1016\/j.msard.2022.104038_bib0026","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s10072-019-03959-4","article-title":"Four cases of natalizumab-related PML: a less severe course in extended interval dosing?","volume":"40","author":"Scarpazza","year":"2019","journal-title":"Neurol. Sci."},{"issue":"2\u20133","key":"10.1016\/j.msard.2022.104038_bib0027","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1387\/ijdb.082773hs","article-title":"Receptor-mediated uptake and transport of macromolecules in the human placenta","volume":"54","author":"Schneider","year":"2010","journal-title":"Int. J. Dev. Biol."},{"issue":"6","key":"10.1016\/j.msard.2022.104038_bib0028","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s00415-014-7325-8","article-title":"Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients","volume":"261","author":"Sorensen","year":"2014","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2022.104038_bib0029","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41582-018-0082-z","article-title":"Treatment of multiple sclerosis - success from bench to bedside","volume":"15","author":"Tintore","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2022.104038_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101961","article-title":"Pregnancy outcomes amongst multiple sclerosis females with third trimester natalizumab use","volume":"40","author":"Triplett","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2022.104038_bib0031","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/bdrb.20190","article-title":"Embryo\/fetal development in cynomolgus monkeys exposed to natalizumab, an alpha4 integrin inhibitor","volume":"86","author":"Wehner","year":"2009","journal-title":"Birth Defects Res. B Dev. Reprod. Toxicol."},{"issue":"9","key":"10.1016\/j.msard.2022.104038_bib0032","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/jnnp-2015-312221","article-title":"Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation","volume":"87","author":"Weinstock-Guttman","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.msard.2022.104038_bib0033","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000672","article-title":"Pharmacodynamics of natalizumab extended interval dosing in MS","volume":"7","author":"Zhovtis Ryerson","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822005466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822005466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:04:25Z","timestamp":1761901465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822005466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":33,"alternative-id":["S2211034822005466"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104038","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment with natalizumab during pregnancy in multiple sclerosis: The experience of implementing a clinical practice protocol (NAP-30)","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104038"}}